Cite
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
MLA
Xuenong Ouyang, et al. “Phase III Study of Dulanermin (Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2 Ligand) Combined with Vinorelbine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer.” Investigational New Drugs, vol. 36, no. 2, Apr. 2018, pp. 315–22. EBSCOhost, https://doi.org/10.1007/s10637-017-0536-y.
APA
Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, Cheng Huang, Min Tao, Zhehai Wang, Conghua Xie, Qi Wu, Yongqian Shu, Baohui Han, Fengchun Zhang, Yiping Zhang, Chunhong Hu, Xitao Ma, Yongjie Liang, & Anlan Wang. (2018). Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer. Investigational New Drugs, 36(2), 315–322. https://doi.org/10.1007/s10637-017-0536-y
Chicago
Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, et al. 2018. “Phase III Study of Dulanermin (Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2 Ligand) Combined with Vinorelbine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer.” Investigational New Drugs 36 (2): 315–22. doi:10.1007/s10637-017-0536-y.